Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2024-12-09 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces new data from the TELLOMAK Phase 2 study on lacutamab, presented at the American Society of Hematology (ASH) 2024 meeting. It details clinical results, patient profiles, and translational analysis. This type of announcement, which disseminates key scientific or operational updates outside of mandatory periodic financial reports (like 10-K or IR), is typically classified as an Earnings Release (ER) if it relates to financial performance, or a Regulatory Filing (RNS) if it's a general announcement. Since this is a scientific/clinical data presentation announcement, and not a formal financial report, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for non-standard regulatory or material corporate news releases, or potentially an Earnings Release (ER) if the context implies it's tied to a scheduled results announcement, although the focus here is purely clinical data presentation at a conference. Given the content is a press release announcing clinical data presentation at a medical conference, and it is not a formal financial report (10-K, IR, MRQ) or a specific management/dividend announcement, RNS is the most appropriate general regulatory/news category. However, press releases announcing clinical trial data are often categorized as Earnings Releases (ER) if they are part of the company's regular investor communications cycle, even if the content isn't strictly quarterly earnings figures. Given the structure and purpose (announcing significant study results), ER is a strong candidate, but RNS covers general material announcements well. Since it is a press release announcing scientific progress, and not a formal financial report, RNS is chosen as the best fit among the provided options for a material, non-financial-specific announcement.
2024-12-09 French
6-K
Foreign Filer Report
2024-12-06 English
Inside Information / Other news releases
Capital/Financing Update Classification · 1% confidence The document is a press release dated December 6, 2024, announcing a financial agreement and investment between Innate Pharma and IFLI to support the development of IPH6501. It details an upfront investment and potential future investments contingent on milestones, involving the issuance of new shares. This content directly relates to fundraising, financing activities, and capital structure changes (issuance of new shares for investment). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a transcript (CT). Since it is a formal announcement detailing a financing transaction, CAP is the most appropriate classification.
2024-12-06 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document announces a strategic investment and collaboration between Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) concerning the development of IPH6501. It details financial commitments ($3M initial payment, up to $4.9M conditional investments) tied to clinical milestones. This content directly relates to fundraising, financing activities, and capital structure changes (issuance of new shares to IFLI). Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). Since it involves a specific capital transaction (issuance of shares as part of the investment), CAP is the most precise classification.
2024-12-06 French
6-K
Foreign Filer Report
2024-12-03 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated December 3, 2024, announcing that abstracts detailing data on Innate Pharma's drug candidates (lacutamab and SAR443579) have been selected for presentation at the American Society of Hematology (ASH) Annual Congress in December 2024. This is an announcement about scientific data being presented at a medical conference, not the full financial report (10-K), an interim report (IR), or a formal earnings release (ER). It is a communication aimed at investors and the public regarding scientific progress and upcoming presentations. While it contains company information, its primary purpose is to disseminate news about scientific data presentation at an external event. This fits best under the general category of Investor Relations/Regulatory Filings, but given the specific nature of announcing scientific data presentation at a major conference, it aligns closely with general corporate updates often categorized under Investor Relations or Regulatory Filings (RNS). Since there is no specific code for 'Scientific Data Presentation Announcement', and it is a formal press release detailing corporate/scientific progress, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although IP (Investor Presentation) might seem close, this is an announcement *about* presentations, not the presentation itself. Given the context of corporate filings databases, this type of announcement is typically classified as a general regulatory filing or news release.
2024-12-03 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.